CBIO
CRESCENT BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$12.36
+4.39%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.67
- Revenue estimate
- $357.1K
Latest reported
- Last report date
- Jul 30, 2026
- EPS actual
- -$0.74
- EPS estimate
- -$0.74
- Revenue actual
- —
- Revenue estimate
- $357.1K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 3
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- -23.0%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $32
- PT range
- $27 – $36
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Jul 30, 2026 | -$0.74 | -$0.74 | Miss -0.58% | — |
| Apr 29, 2026 | -$0.85 | -$0.70 | Beat 17.65% | $1.0M |
| Nov 6, 2025 | -$1.01 | -$1.27 | Miss -25.74% | — |
| Jul 31, 2025 | -$2.69 | -$4.93 | Miss -83.27% | — |
| May 14, 2025 | -$0.05 | -$0.04 | Beat 20.00% | — |
| Feb 13, 2025 | -$0.16 | -$0.11 | Beat 31.25% | $54.1K |
| Aug 8, 2024 | -$0.17 | -$0.16 | Beat 5.88% | — |
| May 9, 2024 | -$0.16 | -$0.17 | Miss -6.25% | — |
| Nov 3, 2023 | -$0.14 | -$0.14 | In line | — |
| Aug 2, 2023 | -$0.18 | -$0.13 | Beat 27.78% | — |
| May 3, 2023 | -$0.17 | -$0.17 | In line | — |
| Nov 9, 2022 | -$0.26 | -$0.16 | Beat 38.46% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026